We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

437 hedge funds and large institutions have $6.5B invested in Bio-Rad Laboratories Class A in 2024 Q3 according to their latest regulatory filings, with 68 funds opening new positions, 133 increasing their positions, 169 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more call options, than puts

Call options by funds: $6.56M | Put options by funds: $4.64M

20% more capital invested

Capital invested by funds: $5.41B → $6.5B (+$1.09B)

0.72% more ownership

Funds ownership: 84.5%85.21% (+0.72%)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

0% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 68

0% less funds holding

Funds holding: 439437 (-2)

21% less repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 169

Holders
437
Holders Change
-2
Holders Change %
-0.46%
% of All Funds
6.28%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
68
Increased
133
Reduced
169
Closed
68
Calls
$6.56M
Puts
$4.64M
Net Calls
+$1.91M
Net Calls Change
+$8.17M
Name Holding Trade Value Shares
Change
Change in
Stake
RP
276
Rowlandmiller & Partners
Georgia
$295K -$30.2K -95 -10%
BFM
277
Boothbay Fund Management
New York
$292K -$21.9K -69 -7%
Nisa Investment Advisors
278
Nisa Investment Advisors
Missouri
$292K +$102K +322 +59%
KAS
279
Kestra Advisory Services
Texas
$290K -$33.7K -106 -11%
TMAM
280
Tokio Marine Asset Management
Japan
$290K
BTI
281
Blue Trust Inc
Georgia
$288K +$62.6K +197 +23%
Bank of Nova Scotia
282
Bank of Nova Scotia
Ontario, Canada
$288K -$394K -1,239 -59%
II
283
Inspire Investing
Idaho
$288K -$33K -104 -11%
Wealth Enhancement Advisory Services
284
Wealth Enhancement Advisory Services
Minnesota
$287K -$28.6K -90 -10%
CCM
285
Coldstream Capital Management
Washington
$284K +$6.35K +20 +2%
ProShare Advisors
286
ProShare Advisors
Maryland
$279K -$675K -2,125 -72%
FTDI
287
First Trust Direct Indexing
Massachusetts
$277K +$263K +829 New
UWS
288
Unique Wealth Strategies
Illinois
$270K +$257K +808 New
BNP Paribas Asset Management
289
BNP Paribas Asset Management
France
$269K -$296K -933 -54%
I
290
InceptionR
California
$268K -$273K -859 -52%
GIA
291
Gateway Investment Advisers
Ohio
$263K -$28.6K -90 -10%
SOAG
292
Silver Oak Advisory Group
Oregon
$259K
Lido Advisors
293
Lido Advisors
California
$258K +$7.62K +24 +3%
CAPTRUST Financial Advisors
294
CAPTRUST Financial Advisors
North Carolina
$256K -$71.8K -226 -23%
MYAM
295
Meiji Yasuda Asset Management
Japan
$255K +$242K +761 New
BIAS
296
Beacon Investment Advisory Services
New Jersey
$252K
OAC
297
OMERS Administration Corp
Ontario, Canada
$252K
BCP
298
Blackhawk Capital Partners
Wisconsin
$251K +$238K +749 New
SCM
299
Sterling Capital Management
North Carolina
$246K +$234K +736 New
CB
300
Commerce Bank
Missouri
$240K +$228K +717 New

BIO Hedge Fund Activity: Q3 2024 in Review

437 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2024, worth a combined $6.5B — up 20% from $5.41B a quarter earlier.

Fund positioning in BIO was balanced in Q3 2024: 68 funds opened new positions, 68 closed out, 133 added to existing stakes and 169 trimmed.

The largest buyer was VanEck Associates, adding an estimated $205M. The largest seller was Invesco, cutting an estimated $161M.

  • 437 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2024, down from 439 in Q2 2024.
  • Funds reported $6.5B of Bio-Rad Laboratories Class A stock for Q3 2024, up 20% quarter-over-quarter.
  • 68 funds opened new Bio-Rad Laboratories Class A positions in Q3 2024 and 68 closed out, a net change of 0 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q3 2024 was VanEck Associates, an estimated $205M added.
  • The largest Bio-Rad Laboratories Class A seller in Q3 2024 was Invesco, an estimated $161M sold.

Based on aggregated 13F filings for Q3 2024.